
Medline Inc (MDLN) Stock Forecast & Price Target
Medline Inc (MDLN) Analyst Ratings
Bulls say
Medline Inc demonstrated strong financial performance in F2024, with Supply Chain Solutions generating $13 billion in revenue, reflecting a 12% year-over-year growth, while Medline Brand contributed $12.5 billion, up 7.8% year-over-year. The company's robust growth trajectory is evident in its adjusted EBITDA of $3.4 billion for Medline Brand, resulting in a corporate-wide EBITDA margin of 13.2% and a significant increase in Supply Chain Solutions' EBITDA, which rose by 32% year-over-year. Medline's resilience during economic downturns, as indicated by revenue growth during the 2008-2009 financial crisis and the COVID pandemic, underscores its ability to capitalize on the increasing demand for essential medical supplies driven by demographic trends and rising healthcare needs.
Bears say
The financial outlook for Medline Inc is dimmed by several critical factors impacting the healthcare sector, including low margins, elevated inflation, and staffing shortages, all of which are straining hospital profit and loss statements. Furthermore, the potential decline in insured patients may lead to reduced hospital volumes, prompting CFOs to anticipate tighter budgets, thereby threatening Medline's revenues and earnings potential. Additionally, the company's substantial debt load may restrict opportunities for mergers and acquisitions, limiting growth and leaving Medline vulnerable to competitive pressures in an already consolidated industry.
This aggregate rating is based on analysts' research of Medline Inc and is not a guaranteed prediction by Public.com or investment advice.
Medline Inc (MDLN) Analyst Forecast & Price Prediction
Start investing in Medline Inc (MDLN)
Order type
Buy in
Order amount
Est. shares
0 shares